A procedure has been established for the in vitro assessment of hollow fibre haemodialysis membranes. A 30 ml syringe containing 20 ml of fresh non-anticoagulated blood was mounted onto a non-pulsatile syringe pump and blood was perfused through minimodules constructed from 80 fibres retrieved from Cuprophan (Baxter ST15), cellulose acetate (M57-12, JMS Co Ltd, Hiroshima, Japan), and AN69HF (Filtral 20, Hospal, France) dialysers. Samples were collected before perfusion, 3, 6, 9 and 12 minutes. The modules were clamped vertically to minimise the effect of red cell pooling and the dialysate compartment was filled with 0.9% saline to minimise ultrafiltration. After sample processing, complement C3a, thrombin-antithrombin III complexes, prothrombin F1 + 2, and factor XII-like activity were evaluated. The results indicated that the system could discriminate between the membranes evaluated and therefore was a relevant procedure for the assessment of hollow fibre haemodialysis membranes.
ForbesC.D., CourtneyJ.M.. Thrombosis and artificial surfaces. In: BloomA.L., ForbesC.D., ThomasD.P., TuddenhamE.G.D., eds. Thrombosis and haemostasis3rd ed.Edinburgh: Churchill Livingstone, 1994; 1301–24.
2.
LambaN.M.K., YinH.Q., GaylorJ.D.S., CourtneyJ.M., LoweG.D.O.. In vitro assessment of biomaterials for extracorporeal applications.Int J Artif Organs1994; 17(8): 433.
3.
YinH.Q., LambaN.M.K., GaylorJ.D.S., CourtneyJ.M., BlassC.R., LoweG.D.O.. In vitro blood compatibility assessment of tubular materials.Int J Artif Organs1994; 17(8): 433.
4.
CourtneyJ.M., SundaramS., LambaN.M.K., ForbesC.D.. Monitoring of the blood response in blood purification.Artif Organs1993; 17: 260–6.
5.
TraversM., SimpsonK., CourtneyJ.M., BradleyH.E., PollockJ.C., ForbesC.D.. Biomaterials and the immune response. In: BarbenelJ.C., FisherA.C., GaylorJ.D.S., AngersonW.J., SheldonC.D., eds. Blood flow in artificial organs and cardiovascular prostheses.Oxford: Clarendon Press, 1989; 113–21.
6.
RobertsonL.M., CourtneyJ.M., IrvineL., JonesC., LoweG.D.O.. Modification of the blood compatibility of hemodialysis membranes.Artif Organs1990; 14(suppl 3): S41–S43.
7.
YuJ., LambaN.M.K., CourtneyJ.M.. Influence of phosphorylcholine polar groups on protein adsorption and complement activation.Int J Artif Organs1994; 17: 499–504.
8.
JanatovaJ., CheungA.K., ParkerC.J.. Biomedical polymers differ in their capacity to activate complement.Complement and Inflammation1991; 8: 161–9.
9.
ChenowethD.E.. Complement activation produced by biomaterials.Trans ASAIO1986; 22: 226–32.
10.
KazatchkineM.D., Haeffner-CavaillonN.. Mechanisms and consequences of complement activation. In: HörlW.H., SchollmeyerP.J., eds. Perspectives in hemodialysis, peritoneal dialysis, arteriovenous hemofiltration and plasmapheresis.New York: Plenum Press, 1989; 19–26.
11.
LabarreD., MontdargentB., CarrenoM-P, MailletF.. Strategy for in vitro evaluation of the interaction between biomaterials and the complement system.J Appl Biomaterials1993; 4: 231–40.
12.
BowryS.K., CourtneyJ.M., PrenticeC.R.M., DouglasJ.T.. Utilization of the platelet release reaction in the blood compatibility assessment of polymers.Biomaterials1984; 5: 289–92.
13.
TeitelJ.M., BauerK.A., LauH.K., RosenbergR.D.. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2 fragment and the thrombin -antithrombin complex.Blood1982; 59: 1086–97.
14.
PelzaH., SchwartA., StuberW.. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide.Thromb Haem1991; 65: 153–9.
15.
BauerK.A., RosenbergR.D.. Thrombin generation in acute promyelocyte leukemia.Blood1984; 64: 791–6.
16.
IrvineL., SundaramS., CourtneyJ.M., TaggartD.P., WheatleyD.J., LoweG.D.O.. Monitoring of factor XII activity and granulocyte elastase release during cardiopulmonary bypass.Trans ASAIO1991; 37: 569–71.
17.
SundaramS., CourtneyJ.M., TaggartD.P.. Biocompatibility of cardiopulmonary bypass: influence on blood compatibility of device type, mode of blood flow and duration of application.Int J Artif Organs1994; 17: 118–28.
MatataB.M., WarkS., SundaramS.. In vitro contact phase activation with haemodialysis membranes: role of pharmaceutical agents.Biomaterials1995; 16(17): 1305–12.
20.
GallimoreM.J., ReesW.A., FuhrerG., HellerW.. A direct chromogenic peptide substrate assay for Hageman factor (FXII).J Fibrinolysis1987; 1: 123–7.
21.
ChenowethD.E.. Complement activation during hemodialysis: clinical observations, proposed mechanisms and theoretical implications.Artif Organs1984; 8: 281–7.
22.
BoschT., SchmidtB., SamtlebenW., GurlandH.J.. Biocompatibility and clinical performance of a new modified cellulose membrane.Clin Nephrol1986; 26(suppl 1): S522–S529.
23.
MollS., MoerlooseP.. De, Reber G, Schifferli J, Leski M. Comparison of two hemodialysis membranes, polyacrylonitrile and cellulose acetate, on complement and coagulation systems.Int J Artif Organs1990; 13: 273–9.
24.
KandusA., PonikvarR., DrinovecJ., KladnikS., IvanovichP.. Anaphylatoxins C3a nad C5a adsorption on acrylonitrile membrane of hollow-fiber and plate dialyzer- and in vivo study.Int J Artif Organs1990; 13: 176–80.
25.
CheungA.K., ParkerC.J., WilcoxL.A., JanatovaJ.. Activation of complement by hemodialysis membranes: polyacrylonitrile binds more C3a than Cuprophan.Kidney Int1990; 37: 1055–9.
